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Background
Preclinical and clinical data suggest that combination of a
BRAF and a MEK inhibitor (BRAFi, MEKi) may increase
the efficacy over BRAFi monotherapy in BRAF-mutant
metastatic melanoma and that addition of a MEKi may
overcome or delay resistance to BRAFi.
Materials and methods
This phase Ib/II study is evaluating the combination of
LGX818, a potent, selective BRAF inhibitor, and MEK162,
a selective MEK1/2 inhibitor, in patients with BRAF-
mutant tumors (NCT01543698). The objectives for the
phase Ib portion of the study were determination of the
maximum tolerated dose (MTD) and/or recommended
phase II dose (RP2D) for daily (qd) LGX818 + twice daily
(bid) MEK162. Dose escalation was guided by a Bayesian
logistic regression model with overdose control.
Results
At the time of data cut-off (March 8, 2013), 30 patients
were enrolled (melanoma, n =23 [9 BRAFi-naïve,
14 BRAFi-pretreated]; papillary thyroid cancer, n = 3
[2 BRAFi-naïve, 1 BRAFi-pretreated]; metastatic colorectal
cancer, n = 4 [2 BRAFi-naïve, 2 BRAFi-pretreated]) and
treated at the following dose levels (DLs) with LGX818 qd
+ MEK162 bid, respectively: 50 mg + 45 mg, 100 mg + 45
mg, 200 mg + 45 mg, 400 mg + 45 mg, 450 mg + 45 mg,
and 600 mg + 45 mg. One dose limiting toxicity, grade 3
alanine aminotransferase elevation, was reported at the 600
mg + 45 mg DL. The MTD was not yet determined and
two RP2Ds have been declared: 600 mg + 45 mg and 450
mg + 45 mg. Common adverse events (≥ 20%, all grades)
suspected to be treatment related were nausea, diarrhea,
fatigue, visual impairment, and headache. No events of
fever, hyperkeratosis, or squamous cell carcinoma were
observed. Among patients evaluable for response, complete
response was observed in 1/9 (11%) BRAFi-naïve mela-
noma patients and partial responses were observed in
7/9 (78%) BRAFi-naive melanoma patients, 3/14 (21%)
BRAFi-pretreated melanoma patients, and 2/3 (67%) thyr-
oid cancer patients.
Conclusions
Preliminary data indicate that the combination of
LGX818 + MEK162 is active and demonstrates no
substantial increases in adverse events compared to
single-agent therapies. The absence of fever, hyperkeratosis,
and squamous cell carcinoma suggest a distinct safety
profile for this BRAFi/MEKi combination. Enrollment
continues in the phase II portion of this study where the
efficacy of LGX818 600 mg qd + MEK162 45 mg bid is
being assessed.
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